Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 70

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 70
---
 on our industry and customers is unknown and difficult to predict. As additional new tariffs, legislation and/or regulations are
implemented, or if existing trade agreements are renegotiated or if China or other affected countries take retaliatory trade actions, such changes could have a material adverse effect on our clinical development plans, business, financial
condition, results of operations or cash flows.

Risk Related to Aadi

For more information regarding risks related to Aadi’s historical business, as well as other risk factors applicable to Aadi and its industry, see
“Aadi Risk Factors” beginning on page [●].

- 46 -

THE DIVESTITURE

The following is a discussion of the Divestiture. The description of the Divestiture Agreement in this section and elsewhere in this proxy statement is qualified in its entirety by reference to the complete text of the Divestiture Agreement, which is attached as Annex A to this proxy statement. This summary does not purport to be complete and may not contain all of the information about the Divestiture that is important to you. You are encouraged to read the Purchase Agreement carefully and in its entirety, as it is the legal document that governs the Divestiture.

Parties to the Divestiture

Aadi Bioscience, Inc.

Aadi is a precision oncology
company making bold choices in applying technology to efficiently deliver improved therapies for people with difficult-to-treat cancers. Aadi is a corporation organized under the laws of the State of Delaware. Shares of Aadi common stock are listed
on the Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “AADI.”

Aadi Subsidiary, Inc.

Aadi Sub is wholly owned subsidiary of Aadi and the operating company for the FYARRO Business. Aadi Sub is a corporation organized under the laws of the State
of Delaware.

KAKEN PHARMACEUTICAL CO., LTD.

KAKEN
PHARMACEUTICAL CO., LTD. (“Kaken Parent”) develops, produces, and sells pharmaceuticals and agrochemicals. Kaken Parent’s products are mainly for orthopedics and dermatology. Kaken also manufactures feed additives.

KAKEN INVESTMENTS INC.

KAKEN INVESTMENTS INC.
(“Kaken”) was formed on December 13, 2024, for the purpose of engaging in the transactions contemplated by the Divestiture Agreement. Kaken has not engaged in any business activities other than as incidental to its formation and in
connection with